ACLARIS THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

13 Nov 2024 09:53:10 By NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

11 Nov 2024 09:48:00 By NetDania Notify

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 Jul 2024 16:01:43 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

07 May 2024 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Provides Corporate Update

19 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

05 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

18 Sep 2023 07:00:00 By Nasdaq GlobeNewswire